e-learning
resources
Stockholm 2007
Tuesday 18.09.2007
Prognostic laboratory tests in community-acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The prognostic importance of plasma D-dimer levels in patients with community acquired pneumonia
F. Alatas, C. Naz, G. Ak, H. Yildirim, M. Metintas, S. Erginel (Eskisehir, Turkey)
Source:
Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Session:
Prognostic laboratory tests in community-acquired pneumonia
Session type:
Oral Presentation
Number:
2924
Disease area:
Respiratory critical care, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Alatas, C. Naz, G. Ak, H. Yildirim, M. Metintas, S. Erginel (Eskisehir, Turkey). The prognostic importance of plasma D-dimer levels in patients with community acquired pneumonia. Eur Respir J 2007; 30: Suppl. 51, 2924
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Validation of a computer predictive model to stratify risk and site of care in community acquired pneumonia (CAP)
Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches
Year: 2005
Defining stability in pneumonia and the non-responding pneumonia
Source: Annual Congress 2005 - Outcome in severe pneumonia
Year: 2005
Improving outcome in elderly patients with pneumonia
Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI
Year: 2005
D-dimer is an independent marker predicting severity in community acquired pneumonia
Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections
Year: 2008
Quality-indicators and prognostics in CAP in three populations
Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches
Year: 2005
Plasma fibrinogen concentration is an independent marker of severity in patients with community acquired pneumonia
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Factors related to obtain an etiological diagnosis in community acquired pneumonia (CAP)
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007
The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia
Source: Eur Respir J 2004; 24: Suppl. 48, 241s
Year: 2004
The usage of thiotriazolin in complex treatment of patients with community acquired pneumonia
Source: Eur Respir J 2005; 26: Suppl. 49, 579s
Year: 2005
C-reactive protein (CRP) as a marker of disease severity in community acquired pneumonia patients with sepsis
Source: Annual Congress 2012 - Infections and sepsis in the ICU
Year: 2012
Clinical profile and outcomes of patients with moderate and high risk community acquired pneumonia with mixed pathogens
Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication
Year: 2007
Does the serum C-reactive protein (CRP) predict adverse outcomes in patients admitted with community acquired pneumonia?
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
The role of procoagulant activity in patients with community acquired pneumonia
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012
Virusologic research in healthy persons of closed collectives
Source: Annual Congress 2005 - Host-pathogen interaction in respiratory virus infections
Year: 2005
Biological markers in hospitalised patients with community acquired pneumonia (CAP)
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010
Determining the prognostic value of procalcitonin in ICU patients who developed hospital acquired pneumonia and comparing with sencitive CRP
Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia
Year: 2009
Predictive value of plasma D-dimer in patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010
Admission CRP and D-dimer levels can identify high-risk patients with community-acquired pneumonia
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010
An unbalanced inflammatory response on admission impacts clinical stability in hospitalized patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
The clinical efficiency of thiotriazolin in complex treatment of patients with community acquired pneumonia of the 3
rd
group
Source: Eur Respir J 2007; 30: Suppl. 51, 548s
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept